Progression of renal failure with anaemia and multiple effects of angiotensin-converting enzyme inhibitor in rats with renal mass reduction

Pharmacological Research

Volumn 47, Issue 3, 2003, Pages 243-252

  Yatsu, Takeyuki ^a   Sanagi, Masanao ^a   Fujimori, Akira ^a   Tomura, Yuichi ^a   Hayashi, Kazumi ^a   Tanahashi, Masayuki ^a   Inagaki, Osamu ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

ACE inhibition; Anaemia; Monocyte macrophage; Progressive renal failure; Proteinuria; Renal fibrosis; Renal mass reduction; Renoprotection

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; LISINOPRIL;

ANEMIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURGERY; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GLOMERULOPATHY; HEMATOCRIT; HEMATOLOGY; HISTOLOGY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY TUMOR; MACROPHAGE; MALE; MONOCYTE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL;

EID: 0037370425     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(02)00321-3     Document Type: Article

References (47)

1. Ifudu O., Feldman J., Friedman E.A. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N. Engl. J. Med. 334:1996;420-425.
2. Lewis E.J., Hunsicker L.G., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329:1993;1456-1462.
3. Penno G., Chaturvedi N., Talmud P.J., Cotroneo P., Manto A., Nannipieri M.et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes. 47:1998;1507-1511.
4. Maschio G., Alberti D., Janin G., Locatelli F., Mann J.F., Motolese M.et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N. Engl. J. Med. 334:1996;939-945.
5. Ruggenenti P., Perna A., Gherardi G., Garini G., Zoccali C., Salvadori M.et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 354:1999;359-364.
6. Donnelly S., Shah B.R. Erythropoietin deficiency in hyporeninemia. Am. J. Kidney Dis. 33:1999;947-953.
7. Hirakata H., Onoyama K., Hori K., Fujishima M. Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin. Nephrol. 26:1986;27-32.
8. Vlahakos D.V., Balodimos C., Papachristopoulos V., Vassilakos P., Hinari E., Vlachojannis J.G. Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients. Clin. Nephrol. 43:1995;53-59.
9. Brenner B.M., Lawler E.V., Mackenzie H.S. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 49:1996;1774-1777.
10. Anderson S., Meyer T.W., Rennke H.G., Brenner B.M. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 76:1985;612-619.
11. Badid C., Vincent M., McGregor B., Melin M., Hadj-Aissa A., Veysseyre C.et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int. 58:2000;51-61.
12. Noda M., Matsuo T., Fukuda R., Ohta M., Nagano H., Shibouta Y.et al. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int. 56:1999;898-909.
13. Shimamura T., Morrison A.B. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am. J. Pathol. 79:1975;95-106.
14. Anonymous. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997;349:1787-92.
15. Cinotti GA, Zucchelli PC, Collaborative Study Group. Effect of lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephrol Dial Transplant 2001;16:961-6.
16. Katsumata H., Suzuki H., Ohishi A., Nakamoto H., Saruta T., Sakaguchi H. Effects of antihypertensive agents on blood pressure and the progress of renal failure in partially nephrectomized spontaneously hypertensive rats. Lab Invest. 62:1990;474-480.
17. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
18. Diamond J.R., Kees-Folts D., Ding G., Frye J.E., Restrepo N.C. Macrophages, monocyte chemoattractant peptide-1, and TGF-β1 in experimental hydronephrosis. Am. J. Physiol. 266:1994;F926-F933.
19. Brenner B.M., Meyer T.W., Hostetter T.H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med. 307:1982;652-659.
20. Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 357:2001;1601-1608.
21. Zhang H., Wada J., Kanwar Y.S., Tsuchiyama Y., Hiragushi K., Hida K.et al. Screening for genes up-regulated in 5/6 nephrectomized mouse kidney. Kidney Int. 56:1999;549-558.
22. Mackenzie H.S., Brenner B.M. Current strategies for retarding progression of renal disease. Am. J. Kidney Dis. 31:1998;161-170.
23. Gomez-Garre D., Largo R., Tejera N., Fortes J., Egido J. Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension. 37:2001;1171-1178.
24. Remuzzi G., Ruggenenti P., Benigni A. Understanding the nature of renal disease progression. Kidney Int. 51:1997;2-15.
25. Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 339:1998;1448-1456.
26. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.
27. Hostetter T.H., Olson J.L., Rennke H.G., Venkatachalam M.A., Brenner B.M. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am. J. Physiol. 241:1981;F85-F93.
28. Slataper R., Vicknair N., Sadler R., Bakris G.L. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch. Int. Med. 153:1993;973-980.
29. Kasiske B.L., Kalil R.S., Ma J.Z., Liao M., Keane W.F. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann. Int. Med. 118:1993;129-138.
30. Remuzzi A., Imberti O., Puntorieri S., Malanchini B., Macconi D., Magrini L.et al. Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats. Am. J. Physiol. 267:1994;F1034-F1044.
31. Hamar P., Peti-Peterdi J., Szabo A., Becker G., Flach R., Rosivall L.et al. Interleukin-2-dependent mechanisms are involved in the development of glomerulosclerosis after partial renal ablation in rats. Exp. Nephrol. 9:2001;133-141.
32. Remuzzi G., Zoja C., Gagliardini E., Corna D., Abbate M., Benigni A. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J. Am. Soc. Nephrol. 10:1999;1542-1549.
33. KIP1 after unilateral ureteral obstruction is independent of angiotensin II. Kidney Int. 61:2002;68-79.
34. Matsumoto K., Atkins R.C. Glomerular cells and macrophages in the progression of experimental focal and segmental glomerulosclerosis. Am. J. Pathol. 134:1989;933-945.
35. Assoian R.K., Fleurdelys B.E., Stevenson H.C., Miller P.J., Madtes D.K., Raines E.W.et al. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc. Natl. Acad. Sci. U.S.A. 84:1987;6020-6024.
36. Porreca E., Di Febbo C., Mincione G., Reale M., Baccante G., Guglielmi M.D.et al. Increased transforming growth factor-beta production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension. 30:1997;134-139.
37. Kaneto H., Morrissey J., Klahr S. Increased expression of TGF-β1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int. 44:1993;313-321.
38. Peters H., Border W.A., Noble N.A. Targeting TGF-β overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int. 54:1998;1570-1580.
39. Zoja C., Donadelli R., Corna D., Testa D., Facchinetti D., Maffi R.et al. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. Am. J. Kidney Dis. 29:1997;254-264.
40. Border W.A., Noble N.A. Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension. 31:1998;181-188.
41. Sharma K., Eltayeb B.O., McGowan T.A., Dunn S.R., Alzahabi B., Rohde R.et al. Captopril-induced reduction of serum levels of transforming growth factor-β1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am. J. Kidney Dis. 34:1999;818-823.
42. Ito Y., Aten J., Bende R.J., Oemar B.S., Rabelink T.J., Weening J.J.et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 53:1998;853-861.
43. Eschbach J.W. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 35:1989;134-148.
44. Freudenthaler S.M., Schreeb K., Korner T., Gleiter C.H. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur. J. Clin. Invest. 29:1999;16-23.
45. Onoyama K., Sanai T., Motomura K., Fujishima M. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J. Cardiovasc. Pharmacol. 13(Suppl 3):1989;S27-S30.
46. Freudenthaler S.M., Lucht I., Schenk T., Brink M., Gleiter C.H. Dose-dependent effect of angiotensin II on human erythropoietin production. Pflügers Arch. 439:2000;838-844.
47. Gossmann J., Burkhardt R., Harder S., Lenz T., Sedlmeyer A., Klinkhardt U.et al. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int. 60:2001;83-86.